[go: up one dir, main page]

AU5160499A - 3-(4-amino-5-ethylpyrimidine-2-yl)-1-(2-fluorobenzyl)-1h-pyr zolo(3,4-b)pyridine - Google Patents

3-(4-amino-5-ethylpyrimidine-2-yl)-1-(2-fluorobenzyl)-1h-pyr zolo(3,4-b)pyridine

Info

Publication number
AU5160499A
AU5160499A AU51604/99A AU5160499A AU5160499A AU 5160499 A AU5160499 A AU 5160499A AU 51604/99 A AU51604/99 A AU 51604/99A AU 5160499 A AU5160499 A AU 5160499A AU 5160499 A AU5160499 A AU 5160499A
Authority
AU
Australia
Prior art keywords
ethylpyrimidine
zolo
pyr
fluorobenzyl
pyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU51604/99A
Other languages
English (en)
Inventor
Cristina Alonso-Alija
Klaus Dembowsky
Achim Feurer
Chantal Furstner
Joachim Hutter
Elisabeth Perzborn
Elke Stahl
Johannes-Peter Stasch
Alexander Straub
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Publication of AU5160499A publication Critical patent/AU5160499A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU51604/99A 1998-07-29 1999-07-16 3-(4-amino-5-ethylpyrimidine-2-yl)-1-(2-fluorobenzyl)-1h-pyr zolo(3,4-b)pyridine Abandoned AU5160499A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19834045A DE19834045A1 (de) 1998-07-29 1998-07-29 (4-Amino-5-ethylpyrimidin-2-yl)-1-(2-fluorbenzyl)-1H-pyrazolo[3,4-b]pyridin
DE19834045 1998-07-29
PCT/EP1999/005071 WO2000006567A1 (fr) 1998-07-29 1999-07-16 3-(4-amino-5-ethylpyrimidin-2-yl)-1-(2-fluorbenzyl)-1h-pyrazolo[3,4-b]pyridine

Publications (1)

Publication Number Publication Date
AU5160499A true AU5160499A (en) 2000-02-21

Family

ID=7875638

Family Applications (1)

Application Number Title Priority Date Filing Date
AU51604/99A Abandoned AU5160499A (en) 1998-07-29 1999-07-16 3-(4-amino-5-ethylpyrimidine-2-yl)-1-(2-fluorobenzyl)-1h-pyr zolo(3,4-b)pyridine

Country Status (5)

Country Link
EP (1) EP1104421A1 (fr)
JP (1) JP2002521481A (fr)
AU (1) AU5160499A (fr)
DE (1) DE19834045A1 (fr)
WO (1) WO2000006567A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8114400B2 (en) 2006-11-21 2012-02-14 Bayer Pharma Aktiengesellschaft Aza-bicyclic compounds and their use as stimulators of soluble guanylate cyclase

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10021069A1 (de) * 2000-04-28 2001-10-31 Bayer Ag Substituiertes Pyrazolderivat
EP1339716B1 (fr) 2000-11-22 2004-11-03 Bayer HealthCare AG derives de pyrazolopyridine substitues par un lactame
DE10057754A1 (de) * 2000-11-22 2002-05-23 Bayer Ag Neue Sulfonamid-substituierte Pyrazolopyridinderivate
DE10057751A1 (de) 2000-11-22 2002-05-23 Bayer Ag Neue Carbamat-substituierte Pyrazolopyridinderivate
AR031176A1 (es) * 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10122894A1 (de) * 2001-05-11 2002-11-14 Bayer Ag Neue Sulfonat-substituierte Pyrazolopyridinderivate
ITMI20011308A1 (it) * 2001-06-21 2002-12-21 Nicox Sa Farmaci per il dolore cronico
DE10140421A1 (de) * 2001-08-17 2003-03-06 Bayer Ag Neue Kombination
DE10220570A1 (de) * 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
DE10222550A1 (de) * 2002-05-17 2003-11-27 Bayer Ag Substituierte Benzyl-pyrazolopyridine
DE10232572A1 (de) 2002-07-18 2004-02-05 Bayer Ag Neue 2,5-disubstituierte Pyrimidinderivate
DE10232571A1 (de) 2002-07-18 2004-02-05 Bayer Ag 4-Aminosubstituierte Pyrimidinderivate
DE10244810A1 (de) 2002-09-26 2004-04-08 Bayer Ag Neue Morpholin-überbrückte Indazolderivate
DE102006043443A1 (de) 2006-09-15 2008-03-27 Bayer Healthcare Ag Neue aza-bicyclische Verbindungen und ihre Verwendung
DE102007026392A1 (de) 2007-06-06 2008-12-11 Bayer Healthcare Ag Lösungen für die Perfusion und Konservierung von Organen und Geweben
DE102007028406A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028407A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028319A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028320A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
EP2138178A1 (fr) 2008-06-28 2009-12-30 Bayer Schering Pharma Aktiengesellschaft Oxazolidinones pour le traitement de maladie pulmonaire obstructive chronique (MPOC) et/ou de l'asthme
DE102008063992A1 (de) 2008-12-19 2010-09-02 Lerner, Zinoviy, Dipl.-Ing. Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
UY33041A (es) 2009-11-27 2011-06-30 Bayer Schering Pharma Aktienegesellschaft Procedimiento para la preparaciòn de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificaciòn para el uso como principio activo farmacèutico
NZ715101A (en) 2009-11-27 2017-07-28 Adverio Pharma Gmbh Method for producing methyl-{ 4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl} methyl carbamate and its purification for use thereof as pharmaceutical substance
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
HUE031029T2 (en) 2011-11-25 2017-06-28 Adverio Pharma Gmbh Method for producing substituted (z)-alpha-fluoro-beta-amino-acrylaldehydes
WO2013167669A1 (fr) 2012-05-10 2013-11-14 Bayer Pharma Aktiengesellschaft Anticorps capables de lier au facteur de coagulation xi et/ou à sa forme activée, le facteur xia, et utilisations de ceux-ci
AP2015008670A0 (en) 2013-02-21 2015-08-31 Adverio Pharma Gmbh Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-B]pyridino-3-yl]pyrimidino-5-yl} methyl carbamate
CA3006764A1 (fr) 2015-12-14 2017-06-22 Ironwood Pharmaceuticals, Inc. Utilisation de stimulateurs de la sgc pour le traitement d'un dysfonctionnement du sphincter gastro-intestinal
US20190381039A1 (en) 2016-12-13 2019-12-19 Cyclerion Therapeutics, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF ESOPHAGEAL MOTILITY DISORDERS
JP7090639B2 (ja) 2017-04-11 2022-06-24 サンシャイン・レイク・ファーマ・カンパニー・リミテッド フッ素置換されたインダゾール化合物及びその使用
KR20250141845A (ko) 2018-07-11 2025-09-29 티센토 쎄라퓨틱스 인크. 미토콘드리아 장애의 치료를 위한 sGC 자극제의 용도
CN118772140A (zh) * 2023-04-07 2024-10-15 四川大学 一类化合物及其在治疗hDHODH介导的疾病中的用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19649460A1 (de) * 1996-11-26 1998-05-28 Bayer Ag Neue substituierte Pyrazolderivate

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8114400B2 (en) 2006-11-21 2012-02-14 Bayer Pharma Aktiengesellschaft Aza-bicyclic compounds and their use as stimulators of soluble guanylate cyclase

Also Published As

Publication number Publication date
DE19834045A1 (de) 2000-02-03
JP2002521481A (ja) 2002-07-16
EP1104421A1 (fr) 2001-06-06
WO2000006567A1 (fr) 2000-02-10

Similar Documents

Publication Publication Date Title
AU5160499A (en) 3-(4-amino-5-ethylpyrimidine-2-yl)-1-(2-fluorobenzyl)-1h-pyr zolo(3,4-b)pyridine
AU5280998A (en) 8-substituted-1,3,8-triaza-spiro(4.5)decan-4-on derivatives
AU3770697A (en) 2- and 2,5-substituted phenylketoenols
AU5330998A (en) Avatar kiosk
AU3464599A (en) Aminoalkyl substituted 9h-pyridino(2,3-b)indole and 9h-pyrimidino(4,5-b)indole derivatives
AU4808300A (en) 9h-pyrimido(4,5-b)indole derivatives: crf1 specific ligands
ZA979593B (en) Naphthyridine derivatives.
AU2001259707A1 (en) 6,5-fused bicyclic heterocycles
AU5041600A (en) Sharing open sessions between plural settop terminals
ZA976021B (en) Bicyclic-fused pyridines.
AU2709900A (en) Process for making 2,3-dihalopropanols
AU2426297A (en) Trainable, state-sampled, network controller
AU3041700A (en) Imidazo(4,5-c)-pyridine-4-on-derivatives
MXPA00007634A (es) Nuevos compuestos de triazol (4,5-d) pirimidina.
AU5065999A (en) Naphthyridine derivatives
ZA992072B (en) Substituted pyrroles.
ZA982969B (en) 1,2,3,4-tetrahydro-benzofuro[3,2-c]pyridine derivatives.
ZA993852B (en) Diaza-Spiro (3,5)nonane derivates.
AU2253297A (en) Imidazo{1,2-a}pyridine c-nucleosides as antiviral agents
ZA972829B (en) Novel pyrimido [1,2-a]indoles.
AU2759897A (en) Pyrrolo{2,3-b}pyridine derivatives, useful as radiolabelled d4 receptor ligands
AU5585700A (en) Process for making 2,4,6, 8,10,12- hexanitro- 2,4,6,8,10, 12- hexa azatetracyclo(5.5.0. 05,9.03,11} -dodecane
AU5154699A (en) 4,5,6,7-tetrahydro-thieno(2,3-c)pyridine derivatives
AU6831500A (en) 1h-pirido[3, 4-b]indol-1-one derivatives
PL355849A1 (en) 3-(4,5-dihydroisoxazole-5-yl)benzoylpyrazole

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase